# Retatrutide

*Also known as: Reta, Triple-G*

Triple-agonist (GLP-1/GIP/glucagon) investigational peptide; very potent weight loss.

## Overview

Retatrutide is an investigational once-weekly peptide that acts as a triple agonist of the GLP-1, GIP, and glucagon receptors, in development for obesity and type 2 diabetes and notable for the magnitude of weight loss reported in Phase II data. By co-activating GLP-1 and GIP receptors it drives insulin release, slows gastric emptying, and reduces appetite, while the glucagon receptor activity adds direct hepatic fat oxidation and thermogenesis that dual GLP-1/GIP agents do not provide. The compound has a roughly 147-hour half-life, peaks within roughly 1.7 days of subcutaneous injection, and shows about 80% bioavailability, which is what allows once-weekly dosing with sustained exposure over months. Phase II data show weight loss exceeding current GLP-1 and GLP-1/GIP comparators, while the dominant adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and reduced appetite, alongside the known class considerations around lean mass preservation.

## Pharmacokinetics

- **Model tier:** advanced
- **Half-life:** 6.1 days (147.3333312 hours)
- **Cmax:** 11495.37 nmol/L
- **Tmax:** 1.7 days
- **Bioavailability:** 80%

## Dosing

- **Default dose:** 4 mg
- **Typical range:** 1–12 mg
- **Units:** nmol/L

## Source

- **Label:** Cell Metabolism (retatrutide)
- **URL:** https://www.cell.com/cell-metabolism/pdfExtended/S1550-4131(22)00312-6
- **Notes:** No good bioavailability source.

**Tags:** weight-loss, metabolic

---

**Canonical URL:** https://anabolicdex.com/compounds/retatrutide
**Plot:** https://anabolicdex.com/plot?compound=retatrutide